This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Reply from the Authors: In the preceding letter from Drs. Boiardi, Salmaggi, and Silvani, there appears a brief report of 18 patients who received M-Bacod therapy before irradiation of their brain lymphoma.
"M-Bacod as first treatment for primary CNS lymphoma" reports the results of a regimen of two cycles of M-Bacod in patients with primary CNS lymphoma. A subgroup of nine patients received radiation regardless of tumor response, and another subgroup of nine patients received radiation at the time of tumor recurrence. Their initial results are impressive, with survival ranges of 8 to 58 months in nine patients who are still alive. Unfortunately, the reader would wish to know the toxicities of the therapy, the responses …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Alert Me
Recommended articles
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients
Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy
Journal Club: Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Retinopathy in survivors of primary central nervous system lymphoma